1. Targeting IL-36 in Inflammatory Skin Diseases

   • Ryo Fukaura
   • Masashi Akiyama

   Leading Article 03 March 2023 Pages: 279 - 293

   

2. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus

   • Charl Verwey
   • Shabir A. Madhi

   Review Article Open access 25 April 2023 Pages: 295 - 309

3. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer

   • Motahareh Arjomandnejad
   • Ishani Dasgupta
   • Allison M. Keeler

   Review Article Open access 02 March 2023 Pages: 311 - 329

   

4. Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus

   • Mingshu Huang
   • Weixing Chen
   • Bo Jia

   Review Article 13 May 2023 Pages: 331 - 352

   

5. Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery

   • Amir Hossein Mohammadi
   • Zeinab Ghazvinian
   • Kaveh Baghaei

   Review Article 24 April 2023 Pages: 353 - 374

   

6. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)

   • Valentina D. Gusarova
   • Maxim A. Smolov
   • Rahim R. Shukurov

   Original Research Article 04 April 2023 Pages: 375 - 395

   

7. Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System

   • Hugo Jourdain
   • Léa Hoisnard
   • Mahmoud Zureik

   Original Research Article Open access 06 March 2023 Pages: 397 - 407

   

8. Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

   • Kuan Peng
   • Joseph E. Blais
   • Xue Li

   Original Research Article Open access 23 March 2023 Pages: 409 - 420

   

9. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing

   • Taihang Shao
   • Mingye Zhao
   • Wenxi Tang

   Original Research Article 25 February 2023 Pages: 421 - 432

   

10. Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial

    • Justin Stebbing
    • Yauheni Baranau
    • Sunghyun Kim

    Short Communication Open access 07 March 2023 Pages: 433 - 440

    

11. Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study

    • Douglas J. Rupert
    • Alyssa M. Jordan
    • R. Craig Lefebvre

    Correction 07 March 2023 Pages: 441 - 441